
Overnight lenses that reshape cornea could slow down myopia progression
Chennai: A new type of contact lens that can be worn overnight to help reshape the cornea and slow the eye's elongation, allowing people with myopia, or near-sightedness, to see without glasses or lenses during the day, will be tested in 200 children at city-based Dr Agarwals Eye Hospital for at least one and a half years, along with scientists from Japan.
Myopia is a growing epidemic, afflicting the eyes of children, said the hospital's Chief Clinical Officer, Dr Ashvin Agarwal. People with myopia can see close-up objects clearly, but to read blackboards, engage in cycling, driving, or recognising the faces of people down the road, they may need glasses. "From a prevalence of 4% in 1999 to 21% in 2019, myopia is expected to affect 40% of India's population by 2040 and touch close to 50% by 2050.
We are trying to slow down the progression," he said. Similarly, digital eye strain now affects 50%-60% of children in India, driven by increased screen time.
Orthokeratology lenses are gas-permeable, rigid contact lenses that temporarily reshape the cornea of your eye. "People wear these lenses while they are sleeping. When they wake up and remove these lenses, their cornea holds its new shape, allowing them to see clearly without the need for glasses or daytime contact lenses," he said.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Pinga-Pinga e HBP? Tome isso 1x ao dia se tem mais de 40 anos
Portal Saúde do Homem
Clique aqui
Undo
In refractive errors, the cornea's shape is irregular, causing blurry vision. These lenses exert gentle hydraulic pressure on the tear film beneath the lens, which in turn reshapes the corneal cells, say experts.
This temporary change in corneal curvature allows light to focus properly on the retina. Experts say they work like dental retainers that maintain the shape of teeth. "It must be worn every night. Our test will show who is benefiting from these glasses," he said.
For the study, launched in Feb, Dr Agarwals Eye Hospital has collaborated with Japan's Menicon Co Ltd for joint research on these lenses. This study will check the efficacy and safety of the orthokeratology lens for Indian children. "We aim to develop solutions and raise awareness about the treatment," said Menicon Co Ltd regional director (China and Asia-Oceania) Shunsuke Yamagishi.
These lenses won't be available for sale until doctors evaluate the benefits and side effects. "If this is successful, it will offer freedom from glasses and eventually show us the path towards a cure for myopia," Dr Agarwal said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scroll.in
26 minutes ago
- Scroll.in
Sidharth Sreekumar
What is the scope of using AI for early detection of critical diseases in Indian public healthcare? An excerpt from 'Enter Prompt: Navigating AI in the World's Largest Democracy', by Barsali Bhattacharyya and Sidharth Sreekumar. Barsali Bhattacharyya &


Scroll.in
26 minutes ago
- Scroll.in
Barsali Bhattacharyya
What is the scope of using AI for early detection of critical diseases in Indian public healthcare? An excerpt from 'Enter Prompt: Navigating AI in the World's Largest Democracy', by Barsali Bhattacharyya and Sidharth Sreekumar. Barsali Bhattacharyya &


United News of India
27 minutes ago
- United News of India
Renalyx launches world's first indigenous AI-based Smart Hemodialysis Machine
Pune, June 11 (UNI) Renalyx Health Systems Pvt. Ltd., a pioneering technology innovation company in renal care, has launched RENALYX – RxT 21, the world's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility. RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions. Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues, said release today. RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification. Renalyx has plans to invest INR 800 crores in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also has plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand. The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years, said the release. UNI SP RN